Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS

Redenlab partnered with investigators in Australia and Germany to conduct dysarthria treatment trial in ataxia published in Journal of Neurology

Abstract: We aimed to provide proof-of-principle evidence that intensive home-based speech treatment can improve dysarthria in complex multisystemic degenerative ataxias, exemplified by autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Feasibility and piloting efficacy of speech training specifically tailored to cerebellar dysarthria was examined through a 4-week program in seven patients with rater-blinded assessment of intelligibility (primary outcome) and naturalness and acoustic measures of speech (secondary outcomes) performed 4 weeks before, immediately prior to, and directly after training (intraindividual control design). Speech intelligibility and naturalness improved post treatment. This provides piloting evidence that ataxia-tailored speech treatment might be effective in degenerative cerebellar disease.

See here for study details

Related Post

  • Posted on 15 May, 2025
    MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap for the...
    • Posted on 26 March, 2025
      A recent study published in iScience explores the effects of KAT6B overexpression in mice, shedding light on the behavioral implications...
      • Posted on 18 February, 2025
        Batten disease, or neuronal ceroid lipofuscinosis (NCL), is a devastating childhood dementia that causes progressive loss of speech, language, and...